FSHR rs6166: Understanding the Ser680Asn Variant
The rs6166 variant is a common genetic change in the FSHR gene that results in an amino acid substitution known as Ser680Asn. This variant is frequently studied for its potential influence on how the body responds to follicle-stimulating hormone, which plays a key role in reproductive health and ovarian function.
What each genotype means
Asn680/Asn680 genotype
This genotype is often referred to as the Asn680/Asn680 variant. Research suggests that carriers of this genotype may exhibit different ovarian sensitivity to follicle-stimulating hormone compared to those with the G allele, with some studies associating it with a lower risk of polycystic ovary syndrome (PCOS) in certain populations.
Reported frequencies vary significantly by ancestry, with some studies observing this genotype in approximately 42% of the studied population.
Asn680/Ser680 genotype
This heterozygous genotype, also known as Asn680/Ser680, represents a mix of the two common receptor forms. Associations with ovarian response and PCOS risk are mixed across different ethnic groups, and findings regarding its clinical impact remain a subject of ongoing research.
This is a common genotype, observed in approximately 39% of some studied cohorts.
Ser680/Ser680 genotype
This genotype, also known as Ser680/Ser680, is associated with reduced ovarian sensitivity to follicle-stimulating hormone in some clinical studies, which may influence ovarian response during fertility treatments. Some research also links this genotype to an increased risk of polycystic ovary syndrome (PCOS) and higher baseline levels of certain reproductive hormones, though these associations are not consistent across all populations.
This genotype is less common than the others in many studied populations, appearing in approximately 19% of some cohorts.
What is the rs6166 Variant?
The rs6166 variant, often referred to as Asn680Ser or c.2039A>G, is a single nucleotide polymorphism (SNP) located within the FSHR gene on chromosome 2. This specific change involves an A-to-G substitution that replaces the amino acid asparagine with serine at position 680 in the receptor's intracellular domain. Because this region is involved in the receptor's signaling process, researchers have long investigated whether this structural change alters how the follicle-stimulating hormone receptor functions. It is one of the most widely studied variants in the FSHR gene, particularly in the context of reproductive medicine and fertility research.
The Role of the FSHR Gene
The FSHR gene provides instructions for making the follicle-stimulating hormone receptor, a protein found primarily on the surface of cells in the ovaries and testes. This receptor is a G-protein-coupled receptor that acts as a docking station for follicle-stimulating hormone (FSH). When FSH binds to this receptor, it triggers a cascade of signals inside the cell that are essential for normal gonad development and function. In females, this signaling is critical for the growth and maturation of ovarian follicles, while in males, it supports the production of sperm. Because the receptor is central to these processes, variations in the gene can theoretically influence the sensitivity of these tissues to hormonal signals.
Research and Associations
Research into rs6166 has produced complex and sometimes conflicting results regarding its clinical impact. Many studies have examined its association with ovarian response to stimulation during fertility treatments, with some evidence suggesting that the Ser680 allele may correlate with different levels of sensitivity to FSH. Additionally, the variant has been studied for its potential link to polycystic ovary syndrome (PCOS) risk. However, findings are often population-specific; for example, some meta-analyses have observed a protective effect of the GG genotype against PCOS in certain populations, while other studies show no significant association. Because these results vary by ethnicity and study design, the evidence remains moderate, and the variant is not considered a definitive diagnostic marker for any specific condition.
Interpreting Your Information
It is important to understand that genetic variants like rs6166 represent only one small piece of a much larger biological puzzle. Reproductive health is influenced by a complex interplay of genetics, environment, lifestyle, and other hormonal factors. If you have received information about your genotype for this variant, it is not a medical diagnosis and cannot predict your personal fertility or health outcomes. You should never use this information to make decisions about medical treatments or lifestyle changes without consulting a qualified healthcare professional. If you are undergoing fertility treatments or have concerns about hormonal health, discuss your specific situation with a reproductive endocrinologist or your primary care physician, who can provide guidance based on your full clinical history.
How common is this variant?
The rs6166 variant is common, with a global minor allele frequency reported around 40% in some databases, though frequencies vary significantly across different ancestral groups.
Frequently asked questions
Does the rs6166 variant cause infertility?
No, the rs6166 variant does not cause infertility. While some studies suggest it may influence how the ovaries respond to hormonal stimulation, it is not a direct cause of infertility and is found in many healthy individuals.
Can I use this genotype to predict my response to IVF?
Genetic testing for rs6166 is not a standard tool for predicting IVF outcomes. While researchers study this variant to understand ovarian sensitivity, clinical decisions are based on comprehensive medical evaluations rather than a single SNP.
Is rs6166 linked to PCOS?
Research on the link between rs6166 and PCOS is ongoing and inconsistent. Some studies suggest a potential association, but results vary by population, and it is not considered a reliable diagnostic marker for PCOS.
Should I change my medication based on my rs6166 genotype?
No. You should never change or stop any medication based on genetic test results without speaking to your doctor or pharmacist. Always consult your healthcare provider regarding any concerns about your treatment plan.
Sources & further reading
Educational information only, last refreshed 10/4/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs6166?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in FSHR
Functional polymorphism in the follicle-stimulating hormone receptor promoter modulating ovarian response and gonadotropin requirement during IVF stimulation.
This variant is linked to ovarian dysgenesis, potentially affecting hormonal regulation and physical appearance related to sexual maturation.
This variant is associated with ovarian dysgenesis, which can impact secondary sexual characteristics and physical development.
Common missense variant (Thr307Ala) in the follicle-stimulating hormone receptor gene, associated with variations in ovarian response to gonadotropin stimulation.
Variant in the follicle stimulating hormone receptor gene associated with altered ovarian response.
FSHR intronic variant associated with ovarian response to follicle-stimulating hormone stimulation in assisted reproductive technology.